Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
Wheeling landscaping business could get uprooted for new District 21 preschool
Wheeling Township Elementary District 21 is considering eminent domain proceedings to acquire a landscaping business property... -
Man charged with DUI, endangering life of a child after 4-vehicle crash in Bartlett
A Wheaton man was charged with driving under the influence of alcohol and endangering the life... -
New building expands People’s Resource Center’s capacity
For decades, the People’s Resource Center operated its food pantry and provided social services in a...